Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo Biloba Pills in Coronary Heart Disease With Impaired Glucose Regulation
NCT03483779Phase 4Unknown
- Sponsor
- Xiyuan Hospital
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronary heart disease (CHD) and impaired glucose regulation (IGR) comparing Experimental group:Ginkgo biloba pills with Control group:placebo pills (2 arms). Primary endpoints: Fasting Plasma Glucose at 8 weeks, Postprandial 2h Blood Glucose at 8 weeks and 1 more. Status: unknown.
02
Drugs
ginkgo biloba extract
03
Conditions
coronary heart disease (CHD)impaired glucose regulation (IGR)
Beyond the preview
Go deeper on NCT03483779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483779.